221 related articles for article (PubMed ID: 12386118)
1. Inhibition of human cytochrome P450 activities by kava extract and kavalactones.
Mathews JM; Etheridge AS; Black SR
Drug Metab Dispos; 2002 Nov; 30(11):1153-7. PubMed ID: 12386118
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro.
Mathews JM; Etheridge AS; Valentine JL; Black SR; Coleman DP; Patel P; So J; Burka LT
Drug Metab Dispos; 2005 Oct; 33(10):1555-63. PubMed ID: 16033948
[TBL] [Abstract][Full Text] [Related]
3. Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1.
Li Y; Mei H; Wu Q; Zhang S; Fang JL; Shi L; Guo L
Toxicol Sci; 2011 Dec; 124(2):388-99. PubMed ID: 21908763
[TBL] [Abstract][Full Text] [Related]
4. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes.
Zou L; Henderson GL; Harkey MR; Sakai Y; Li A
Phytomedicine; 2004; 11(4):285-94. PubMed ID: 15185840
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava).
Unger M; Holzgrabe U; Jacobsen W; Cummins C; Benet LZ
Planta Med; 2002 Dec; 68(12):1055-8. PubMed ID: 12494328
[TBL] [Abstract][Full Text] [Related]
6. A UHPLC-UV Method Development and Validation for Determining Kavalactones and Flavokavains in
Tang Y; Fields C
Molecules; 2019 Mar; 24(7):. PubMed ID: 30934989
[TBL] [Abstract][Full Text] [Related]
7. Kavalactones fail to inhibit alcohol dehydrogenase in vitro.
Anke J; Fu S; Ramzan I
Phytomedicine; 2006 Feb; 13(3):192-5. PubMed ID: 16428028
[TBL] [Abstract][Full Text] [Related]
8. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
9. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23.
Ma Y; Sachdeva K; Liu J; Ford M; Yang D; Khan IA; Chichester CO; Yan B
Drug Metab Dispos; 2004 Nov; 32(11):1317-24. PubMed ID: 15282211
[TBL] [Abstract][Full Text] [Related]
10. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
Desta Z; Wu GM; Morocho AM; Flockhart DA
Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
[TBL] [Abstract][Full Text] [Related]
11. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
12. Assessment of drug-drug interaction for silymarin.
Doehmer J; Tewes B; Klein KU; Gritzko K; Muschick H; Mengs U
Toxicol In Vitro; 2008 Apr; 22(3):610-7. PubMed ID: 18249085
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
14. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones.
Nerurkar PV; Dragull K; Tang CS
Toxicol Sci; 2004 May; 79(1):106-11. PubMed ID: 14737001
[TBL] [Abstract][Full Text] [Related]
15. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
[TBL] [Abstract][Full Text] [Related]
16. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro.
Weiss J; Sauer A; Frank A; Unger M
Drug Metab Dispos; 2005 Nov; 33(11):1580-3. PubMed ID: 16051732
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers.
Kanumuri SRR; Mamallapalli J; Nelson R; McCurdy CR; Mathews CA; Xing C; Sharma A
J Ethnopharmacol; 2022 Oct; 297():115514. PubMed ID: 35777607
[TBL] [Abstract][Full Text] [Related]
20. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
